Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

What are the causes of synapse failure in Alzheimer's disease?

29.02.2012
Prof. Jochen Herms heads a new research group at the German Center for Neurodegenerative Diseases (DZNE) and holds a professorship at the Ludwig-Maximilians-Universität in Munich. He studies the cellular basis of neurodegenerative diseases with advanced microscopy technologies.

The degeneration of synapses – the contact sites between nerve cells – is considered to be the main cause of neurodegenerative diseases like Alzheimer's, Parkinson's or prion diseases. As head of a new research group at the German Center for Neurodegenerative Diseases (DZNE), Professor Jochen Herms investigates why synapses degenerate and what can be done to impede the process. Herms also holds the chair "Translational Research in the Field of Neurodegeneration" at the Ludwig-Maximilians-Universität in Munich.

What are the proteins involved in the degradation of synapses? Which cellular changes take place and which drugs may counteract the degenerative process? To answer these questions Herms and his colleagues have specialized on long-term in vivo two-photon microscopy. This method makes it possible to monitor structural changes at synapses in the mouse brain for a period of weeks or months. "This is much more sensitive than observing the behavior of animals. In addition, drawing a parallel to the human diseases is far more straight forward, at least if one assumes synaptic failure as primary cause of neurodegenerative diseases," says Herms.

Recently Herms made the headlines with an approach to developing a new method for early detection and therapy control of Alzheimer's disease. This method aims to detect tau aggregates – protein structures that accumulate in the central nervous system in Alzheimer's disease – in the retina of the eye. Currently, the researchers are still testing the method in animal models. But if the process turns out to be applicable to humans it would be possible to develop new diagnostic tools for Alzheimer’s disease. "Early diagnosis of Alzheimer's is very important because the disease begins long before the first symptoms appear. An effective therapy against Alzheimer's disease has not yet been established and this can most likely be attributed to the fact that in previous clinical studies, therapy started too late," Herms explains.

Herms is very enthusiastic about his appointment with DZNE. "We will only advance in Alzheimer research if we critically bring into question common assumptions and develop new hypotheses. The strong support we receive at DZNE and the critical mass of scientists at DZNE provide us with the right environment required to achieve this goal," he says. At the DZNE, Herms will focus entirely on doing basic research. In this undertaking, he will strongly profit from his medical background and profound knowledge in neuropathology: "Having a clear picture of the disease in humans helps a lot to better assess the relevance of certain observations in animal models," says Herms.

Jochen Herms studied medicine, received his MD from the University Medical Center Hamburg-Eppendorf and then worked at the Max Planck Institute for Biophysical Chemistry in Göttingen in the lab of Otto Creutzfeldt. Afterwards he specialized in neuropathology at the University Göttingen and completed his habilitation on the function of the prion protein in neurons in 1999. Since 2001 he has been professor of neuropathology at the Ludwig-Maximilians-Universität in Munich (LMU), where he was appointed Chair of Translational Research in the Field of Neurodegeneration and joined DZNE in 2011.

Contact information:
Prof. Dr. Jochen Herms
German Center for Neurodegenerative Diseases (DZNE)
Ludwig-Maximilians-Universität Munich
Centre for Neuropathology
Feodor-Lynen Str. 23
81377 Munich
Email: jochen.herms(at)dzne.de
Tel.: +49 (0) 89 / 2180-78010
Daniel Bayer
German Center for Neurodegenerative Diseases (DZNE)
Press- and Public Relations
Email: daniel.bayer(at)dzne.de
Tel: +49 (0) 228 43302 /261

Daniel Bayer | idw
Further information:
http://bit.ly/herms_group
http://www.dzne.de

More articles from Life Sciences:

nachricht What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Porous crystalline materials: TU Graz researcher shows method for controlled growth

07.12.2016 | Materials Sciences

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>